SAKK 16/14-T-cell receptor repertoire metrics predict response to neoadjuvant durvalumab in patients with stage IIIA(N2) NSCLC
SWISS MEDICAL WEEKLY（2021）
关键词
T-cell receptor repertoire, neoadjuvant immune checkpoint inhibitor, tumor mutational burden
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要